T. Rowe Price Associates
ELOX

T. Rowe Price Associates’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

T. Rowe Price Associates’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-568
Closed -$37K – 3072
2021
Q3 		$37K Buy
+568
New +$35K ﹤0.01% 2918

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

T. Rowe Price Associates's ELOX Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2021, closing a stake of 568 shares — an estimated $37K sold.

T. Rowe Price Associates first reported a position in ELOX in Q3 2021 and held it in 1 quarter. The position peaked at $37K in Q3 2021. 38 funds tracked by Wall St. Rank hold ELOX as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 568 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $37K.
  • T. Rowe Price Associates first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • T. Rowe Price Associates's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $37K in Q3 2021.
  • 38 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.